title: Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.
authors.affiliation: Department of Medicine, Division of Hematology, Stanford University, Stanford, CA.|Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Iberri
authors.affiliation: Department of Dermatology, Stanford University, Stanford, CA.
authors.forename: Bernice Y
authors.initials: BY
authors.lastname: Kwong
authors.affiliation: Department of Dermatology, Stanford University, Stanford, CA.
authors.forename: Laurel A
authors.initials: LA
authors.lastname: Stevens
authors.affiliation: Department of Medicine, Division of Hematology, Stanford University, Stanford, CA.
authors.forename: Steven E
authors.initials: SE
authors.lastname: Coutre
authors.affiliation: Department of Pathology, Stanford University, Stanford, CA.
authors.forename: Jinah
authors.initials: J
authors.lastname: Kim
authors.affiliation: Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.
authors.forename: Jean M
authors.initials: JM
authors.lastname: Sabile
authors.affiliation: Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.
authors.forename: Ranjana H
authors.initials: RH
authors.lastname: Advani
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D019468:Disease Management; D005076:Exanthema / Q000175:diagnosis* / Q000209:etiology* / Q000628:therapy; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012720:Severity of Illness Index; D063189:Symptom Assessment
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
keywords: ibrutinib; new leukaemia drugs; new lymphoma drugs; skin toxicity